<DOC>
	<DOCNO>NCT01835496</DOCNO>
	<brief_summary>The objective study evaluate pharmacokinetics deferiprone 3-O-glucuronide metabolite follow administration single 1500 mg dose Ferriprox patient sickle cell disease .</brief_summary>
	<brief_title>Absorption , Metabolism , Excretion Single Dose Ferriprox® Patients With Sickle Cell Disease</brief_title>
	<detailed_description>This single-arm , single-dose study Ferriprox patient sickle cell disease . Patients find eligible visit clinic day receive drug , order reconfirm eligibility undergo baseline assessment , receive single dose 1500 mg Ferriprox fasting condition . Blood urine sample pharmacokinetic assessment collect 10-hour period . Standard safety assessment perform throughout study , patient return safety follow-up .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Deferiprone</mesh_term>
	<criteria>1 . Male female , 1845 year age ( inclusive ) 2 . Diagnosis sickle cell disease , confirm Hb electrophoresis 3 . Body weight ≥ 50 kg 4 . Body mass index ( BMI ) ≥ 18 ≤ 32 kg/m^2 5 . Absolute neutrophil count ( ANC ) &gt; 1.5 x 10^9/L 6 . Women childbearing potential must agree either sexually inactive use acceptable method birth control 14 day prior dose 30 day afterwards 7 . A fertile heterosexual male must agree partner use effective method contraception 14 day prior dose 30 day afterwards 1 . History presence hypersensitivity idiosyncratic reaction Ferriprox 2 . Use Ferriprox within past 3 month 3 . History malignancy 4 . Evidence abnormal liver function ( serum Alanine Transaminase ( ALT ) level &gt; 5 time upper limit normal creatinine level &gt; 2 time upper limit normal ) 5 . A serious , unstable illness , judge Investigator , within past 3 month screen visit include limited hepatic , renal , gastroenterologic , respiratory , cardiovascular , endocrinologic , neurologic immunologic disease 6 . Hemodialysis week prior dose plan day dose 7 . Known difficulty provide blood sample 8 . Disorders surgery gastrointestinal tract may interfere drug absorption may otherwise influence Pharmacokinetic ( PK ) result ( e.g. , resection small large intestine , febrile condition , chronic diarrhea , chronic vomiting , endocrine disease , severe infection , acute inflammation , etc . ) 9 . Clinically significant abnormality 12lead ECG ( e.g. , QT interval correct use Fridericia 's formula ( QTcF ) ≥ 430 m male ≥ 450 ms female ) 10 . Use tobacco/nicotinecontaining product least 3 month prior study drug administration 11 . Use drug within past 14 day metabolize Uridine diphosphate glucosyltransferase enzyme ( UGT1A6 ) hence could affect PK Ferriprox 12 . Treatment investigational drug within past 30 day 5 halflives drug ( whichever longer ) prior study drug administration 13 . Pregnant nursing female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>sickle cell disease</keyword>
	<keyword>iron overload</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Ferriprox</keyword>
	<keyword>deferiprone</keyword>
</DOC>